Physician profile
Mari Hately
NPI 1467447110
$1,194.47
in general payments reported to CMS, 2019-2025
24 companies · $57.40 in 2025
The $57.40 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.12 · 2020: $33.43 · 2021: $360 · 2022: $412 · 2023: $101 · 2024: $191 · 2025: $57.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $349.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $247.48 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $108.49 | 2021-2025 | Airsupra, Breztri |
| Astellas Pharma US INC | $96.96 | 2021-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $92.40 | 2022-2023 | |
| Nestle Healthcare Nutrition INC. | $81.90 | 2021-2022 | |
| Glaxosmithkline, LLC. | $73.06 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.76 | 2021 | |
| Lilly USA, LLC | $53.31 | 2022-2024 | Mounjaro |
| Novo Nordisk INC | $44.74 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $39.76 | 2019-2024 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.16 | 2019-2024 | Xifaxan, Trulance |
| Pfizer INC. | $28.60 | 2019-2024 | |
| Horizon Therapeutics Plc | $27.49 | 2022 | |
| Amgen INC. | $25.15 | 2024 | |
| Eisai INC. | $24.24 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $22.20 | 2024 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $20.30 | 2025 | Zenpep |
| Abbott Laboratories | $18.75 | 2021 | |
| Amarin Pharma, INC. | $18.43 | 2020 | |
| Janssen Pharmaceuticals, INC | $17.05 | 2021 | |
| Allergan, INC. | $15.00 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.62 | 2022 | |
| Vanda Pharmaceuticals INC. | $12.24 | 2021 | |
| Genentech USA, INC. | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mari Hately listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.